Stage III endometrioid adenocarcinoma has a five-year survival rate of about 50% after surgical resection and other treatments, which can vary. Endometrioid adenocarcinoma is a malignant tumor of the reproductive system that is common in women, and the disease is associated with heredity, gene mutation and other factors. Stage III represents a condition in which the tumor invades extra-uterine tissues but does not invade the true pelvis. The main treatment after diagnosis is surgical resection. After surgery, radiotherapy, chemotherapy and endocrine therapy will be used according to the condition. After active treatment, patients with stage III endometrioid adenocarcinoma can have a five-year survival rate of about 50%. After surgery, patients should pay attention to regular checkups and maintain good living habits as prescribed by doctors, which can reduce recurrence and prolong survival time.